Lux Bioscience Brings In $50 Million To Take Luveniq To The Finish Line Alone

The ophthalmology specialist's inside round could take it through to launch of its lead product--or act as leverage in deal negotiations.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet